https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-01 / J Immunother Cancer 2020 07;8(2)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-01 / J Immunother Cancer 2020 07;8(2)2020-07-01 00:00:002021-05-12 07:32:39Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-646
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-6462020-06-30 00:00:002021-11-15 13:19:48Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-06-24 / Mol Ther Oncolytics 2020 Sep;18:295-303
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-06-24 / Mol Ther Oncolytics 2020 Sep;18:295-3032020-06-24 00:00:002021-05-12 07:29:51CD133 mRNA-Loaded Dendritic Cell Vaccination Abrogates Glioma Stem Cell Propagation in Humanized Glioblastoma Mouse Model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-06-21 / J Control Release 2020 Jun;326:63-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-06-21 / J Control Release 2020 Jun;326:63-742020-06-21 00:00:002020-06-21 00:00:00Blockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-06-15 / Nanomedicine 2020 Jun;29:102240
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-06-15 / Nanomedicine 2020 Jun;29:1022402020-06-15 00:00:002020-06-15 00:00:00Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-05-29 / J Clin Oncol 38: 2020 (suppl; abstr e18022)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-05-29 / J Clin Oncol 38: 2020 (suppl; abstr e18022)2020-05-29 00:00:002020-05-29 00:00:00Dendritic cell vaccine as an alternative to opioid analgesia in patients with advanced cervical cancer.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-05-22 / Immunotargets Ther 2020;9:95-104
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-05-22 / Immunotargets Ther 2020;9:95-1042020-05-22 00:00:002020-05-22 00:00:00Dendritic Cell-Based Therapy Using LY6E Peptide with a Putative Role Against Colorectal Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-05-21 / Front Immunol 2020;11:924
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-05-21 / Front Immunol 2020;11:9242020-05-21 00:00:002020-05-21 00:00:00Dendritic Cells and Their Role in Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-05-19 / Medicines (Basel) 2020 May;7(5)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-05-19 / Medicines (Basel) 2020 May;7(5)2020-05-19 00:00:002021-11-15 20:10:42Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-05-13 / Hum Vaccin Immunother 2020 May;:1-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-05-13 / Hum Vaccin Immunother 2020 May;:1-92020-05-13 00:00:002020-05-13 00:00:00Feasibility of dendritic cell-based vaccine against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused protein antigens combined with anti-PD1
